Protecting neutropenic patients from bowel-derived organisms
- PMID: 1684195
- DOI: 10.1016/0195-6701(91)90167-7
Protecting neutropenic patients from bowel-derived organisms
Abstract
Prevention of infection from bowel-derived organisms in neutropenic patients requires both the appropriate use of chemoprophylaxis and close attention to the prevention of cross-colonization or cross-infection with resistant Enterobacteriaceae and pseudomonads. Control of common-source infection and control of Gram-positive infection are also important. The objectives of chemoprophylaxis should be considered and their efficacy regularly assessed. Non-absorbable antibiotics may have an important place in minimizing selection of resistant strains, but absorbed agents such as cotrimoxazole (trimethoprim/sulphamethoxazole) and 4-quinolones offer advantages over these and nalidixic acid as prophylactic agents. Ciprofloxacin prophylaxis is probably more effective at reducing Gram-negative bacteraemia than co-trimoxazole but overall mortality may be higher. Further confirmation and investigation of the reasons for this are needed. Protocols of rational antibiotic prophylaxis and treatment involving these agents can be modified to cover only the Gram-negative superinfections that are likely.
Similar articles
-
Chemoprophylaxis of gram-negative infections in neutropenic patients.Eur Urol. 1990;17 Suppl 1:40-5. doi: 10.1159/000464090. Eur Urol. 1990. PMID: 2162299 Review.
-
The prophylaxis of bacterial infections in neutropenic patients.J Antimicrob Chemother. 1999 Nov;44(5):587-91. doi: 10.1093/jac/44.5.587. J Antimicrob Chemother. 1999. PMID: 10552973 Review. No abstract available.
-
Emerging role of quinolones in the prevention of gram-negative bacteremia in neutropenic cancer patients and in the treatment of enteric infections.Clin Invest Med. 1989 Feb;12(1):61-8. Clin Invest Med. 1989. PMID: 2646056 Review.
-
Infection prophylaxis in neutropenic patients with acute leukaemia--a randomized, comparative study with ofloxacin, ciprofloxacin and co-trimoxazole/colistin.J Antimicrob Chemother. 1990 Nov;26 Suppl D:137-42. doi: 10.1093/jac/26.suppl_d.137. J Antimicrob Chemother. 1990. PMID: 2286588 Clinical Trial.
-
Bowel microorganisms--a target for selective antimicrobial control.J Hosp Infect. 1991 Sep;19 Suppl C:19-41. doi: 10.1016/0195-6701(91)90166-6. J Hosp Infect. 1991. PMID: 1684194 Review.
Cited by
-
Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia.Am J Clin Oncol. 2019 Feb;42(2):138-142. doi: 10.1097/COC.0000000000000498. Am J Clin Oncol. 2019. PMID: 30557164 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical